AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China. It offers cancer differentiation analysis devices and physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.
IPO Year: 2020
Exchange: NASDAQ
Website: anpacbio.com
Date | Price Target | Rating | Analyst |
---|
NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commer
3 - Fresh2 Group Ltd (0001786511) (Issuer)
3 - Fresh2 Group Ltd (0001786511) (Issuer)
3 - Fresh2 Group Ltd (0001786511) (Issuer)
3 - Fresh2 Group Ltd (0001786511) (Issuer)
3 - Fresh2 Group Ltd (0001786511) (Issuer)
3/A - Fresh2 Group Ltd (0001786511) (Issuer)
3 - Fresh2 Group Ltd (0001786511) (Issuer)
SC 13D - Fresh2 Group Ltd (0001786511) (Subject)
SC 13G - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)
SC 13D/A - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)
SC 13D/A - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)
SC 13D/A - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)
SC 13D - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)
SC 13G - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)
SC 13G - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)
SC 13G - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)
Ticker symbol change effective at the market open May 22, 2023 NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that its ticker symbol on the Nasdaq Stock Market ("Nasdaq") will change to "FRES" effective at the open of market trading on May 22, 2023 following the Company's name change from AnPac Bio-Medical Science Co., Ltd to Fresh2 Group Ltd. The Company has tra
NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2023. The annual report on Form 20-F can be accessed on the SEC's website at http://www.sec.gov and the Company's investor rela
NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its annual financial results for the year ended December 31, 2022. Financial Highlights for Fiscal Year 2022 Total revenues were RMB12.0 million (US$1.7 million) in the year ended December 31, 2022, a decrease of 33.0% from RMB18.0 million in the year ended December 31, 2021. Gross margi
NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its unaudited financial results for the first quarter ended March 31, 2023. The Company's financial statements and related financial information for the quarter ended March 31, 2023 are unaudited and have not been reviewed by the Company's independent registered accountant. These financia
New York, April 06, 2023 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the "Offering") of 625,000 American Depositary Shares ("ADSs") priced at $4.00 per ADS, with pre-funded warrants exercisable for 125,000 ADSs and warrants exercisable for 750,000 ADSs for its client AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) (the "Company" or "AnPac"), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-busi
NEW YORK, April 6, 2023 /PRNewswire/-- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares ("ADSs"), pre-funded warrants to purchase ADSs and warrants to purchase ADSs. The Company plans to use the net proceeds from
NEW YORK, April 3, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on March 31, 2023, the Company entered into an asset purchase agreement (the "Agreement") with Easy Hundred Inc. ("Easy Hundred"), a U.S.-based e-commerce company in the foodservice industry, through which the Company will acquire certain fixed assets of Easy Hundred and Easy Hundred's intellectual property relating to ez100, 2Supply an
New York, NY, March 31, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares ("ADSs"), pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering. The Company plans to use the net proceeds from the offer
NEW YORK, March 23, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on March 22, 2023, the Company has been notified by the Nasdaq Hearings Panel ("Panel") of the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company's request for continued listing on The Capital Market has been granted, subject to the requirement that the Company demonstrate on or before Ju
NEW YORK, March 7, 2023 /PRNewswire/ – AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company" (Nasdaq: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today that it has received the first payment in late February 2023 from a Malaysian customer who had signed a US$1.5 million purchase contract for AnPac Bio's Model AP9080 cancer detection devices. The Model AP9080 cancer detection device is based on Company's patented, novel multi-cancer testing technology named Cancer D
8-K - Fresh2 Group Ltd (0001786511) (Filer)
8-K - Fresh2 Group Ltd (0001786511) (Filer)
8-K - Fresh2 Group Ltd (0001786511) (Filer)
8-K - Fresh2 Group Ltd (0001786511) (Filer)
20-F/A - Fresh2 Group Ltd (0001786511) (Filer)
6-K - Fresh2 Group Ltd (0001786511) (Filer)
6-K - Fresh2 Group Ltd (0001786511) (Filer)
424B5 - Fresh2 Group Ltd (0001786511) (Filer)
6-K - Fresh2 Group Ltd (0001786511) (Filer)
6-K/A - Fresh2 Group Ltd (0001786511) (Filer)
PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that effective August 2, 2022, the board of directors appointed Jiawen Kang as a member of the board of directors of the Company (the "Board") and a member of the Audit Committee and Nominating Committee. On that date, the Company also appointed Yuyang Cui as (a) Co-Chairman of the Board and (b) Co-Chief Executive Officer of the Company. As Co-CEO of the Company, Yuyang Cui will be primarily responsible for (i) searching and presentin
PHILADELPHIA, July 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company's Members approved Written Resolutions of a Majority of the Members (the "Resolutions") on July 14, 2022 addressing the removal of directors and officers, re-designation of officers, and change of members of the committees. The Resolutions were approved by 69.29% of the total voting power of the Company entitled to vote at a general meeting in accordance with British Virgin Islands law, which allows Member's resolution
PHILADELPHIA, April 08, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that Dr. Aidong Chen has joined the Company as its board director, Chief Executive Officer and Chairman of the Board of Directors. Dr. Aidong Chen has been a practicing physician and researcher for over 10 years. He has received over 20 global patents on his work and published 91 papers over his career. Dr. Chen has been affiliated with many leading hospitals, including Yijishan Hospital, and Nanjing Medical University. He has replace
PHILADELPHIA, July 23, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ:ANPC), a biotechnology company with operations in China and the United States, today announced that Mr. Chao Feng, who previously worked for two US Fortune 500 Companies in China, has been appointed as an independent director effective July 19, 2021. Mr. Chao Feng will succeed to Ms. Lin Yu, who resigned as a director of the Company for personal reasons, effective on July 19, 2021. Mr. Chao Feng has served as the general manager of Shanghai Zhiruihaochen Information Technology Co., Ltd since 2019, the chairman of the strategy committee of Guangzhou Chengding